Physician profile
Ralph J Turner
NPI 1013950997
$54,194.30
in general payments reported to CMS, 2019-2025
25 companies · $1,631 in 2025
The $1,631 reported for 2025 was more than what 93% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,415 · 2020: $104 · 2021: $7,105 · 2022: $10K · 2023: $14K · 2024: $14K · 2025: $1,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $1,010 · Travel and Lodging: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $17,178.77 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,817.50 |
| Food and Beverage | $1,009.94 |
| Travel and Lodging | $307.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $30,833.54 | 2021-2025 | Nexplanon, Jada System |
| Astellas Pharma US INC | $11,597.84 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $10,453.48 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $290.88 | 2021-2023 | |
| Abbvie INC. | $229.62 | 2020-2025 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma Global Development | $121.92 | 2023 | Veozah |
| Sage Therapeutics, LLC | $109.48 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $77.94 | 2019-2023 | |
| Exeltis, USA INC. | $73.61 | 2020-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $54.14 | 2019-2025 | |
| Allergan, INC. | $41.10 | 2019-2020 | |
| Aesculap, INC. | $40.42 | 2019 | |
| Exact Sciences Corporation | $39.06 | 2025 | Cologuard Collection Kit |
| Axonics, INC. | $37.18 | 2021-2023 | Axonics |
| Amag Pharmaceuticals, INC. | $23.92 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $21.70 | 2025 | |
| Duchesnay USA Incorporated | $21.20 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $20.17 | 2019 | |
| Myovant Sciences INC. | $19.41 | 2021 | |
| Mission Pharmacal Company | $19.33 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.38 | 2025 | Qelbree |
| Lupin INC. | $14.03 | 2019 | |
| Minerva Surgical, INC | $13.76 | 2022 | |
| Therapeuticsmd, INC. | $13.40 | 2019 | |
| Evofem Biosciences, INC. | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.